ConcertAI, a real-world data and artificial intelligence startup for healthcare providers and life science companies, scored $150 million in Series C funding from Sixth Street.
The round bumps the five-year-old company's valuation to $1.9 billion. As part of the deal, Sixth Street's managing director Adam Kaye will join ConcertAI's board, and managing director Lee Mooney will serve as a board...
ConcertAI, a healthcare data science and AI company that focuses on oncology, is expanding its partnership with Janssen Research & Development to improve study design and diversify clinical trials.
The company, formerly known as Concerto HealthAI, said the collaboration will allow it to expand its data sources, move into disease states at earlier stages and provide more access to new...
SymphonyAI Group, a collection of private B2B artificial intelligence companies spanning multiple sectors, announced yesterday that it has acquired TeraRecon, the maker of products for medical-image post-processing and other related products.
As the group’s seventh portfolio company, TeraRecon will continue building out its radiology, cardiology and vascular-surgery AI-imaging support. However,...
Concerto HealthAI, the maker of a clinical insight generation platform that employs real-world data in its analyses, has closed $150 million in aggregate Series B financing. Declaration Partners headed the investments, which also featured Maverick Ventures, AllianceBernstein PCI and SymphonyAI Group.
Concerto boasts 90% year-over-year revenue growth for its business, and paired the funding...
Concerto HealthAI, the maker of a clinical insight generation platform that employs real-world data in its analyses, is racking up the pharma partnerships as of late. Just weeks after the artificial intelligence company agreed to a multi-year deal with Bristol-Myers Squibb, Concerto announced this morning a similar project with Pfizer that will support the latter’s research on precision oncology...
Bristol-Myers Squibb’s research efforts will be getting an artificial intelligence boost thanks to a new multi-year deal signed by the pharmaceutical company and Concerto HealthAI, the maker of a clinical insight generation platform that employs real-world data in its analyses.
According to the announcement, Concerto’s eurekaHealth tool will “accelerate insights through novel health economic...
